Table 1 Demographic and clinical characteristics at baseline of all chronic migraine patients treated with erenumab (N = 160)
From: Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
Variables | |
|---|---|
Females, n (%) | 132 (82.5%) |
Age (y), mean ± SD | 48 ± 14.3 |
CM duration (y), mean ± SD | 12.1 ± 11.0 |
Aura, n (%) | 53 (33.1%) |
Medication overuse, n (%) | 87 (54.4%) |
Monthly migraine days, mean ± SD | 19.8 ± 9.0 |
Monthly headache days, mean ± SD | 23.4 ± 7.3 |
Monthly headache free days, mean ± SD | 3.8 ± 5.7 |
Monthly abortive treatment intake days, mean ± SD | 11.6 ± 8.8 |
HIT-6 score, mean ± SD | 67.6 ± 4.9 |
Number of preventive treatments failed, mean ± SD | 8.3 ± 3.6 |
BoNT/A non-responders, n (%) | 147 (91.9%) |